In our study comparing the effectiveness and cost of DPP-4 inhibitors and biguanides in Japanese T2DM patients, we found no significant differences in long-term incidences of cardio-cerebrovascular events and complications between the two groups, but the daily cost for antidiabetic agents of biguanide use was lower. Here, DPP4 is linked to type 2 diabetes mellitus.